{"id":31063,"date":"2025-02-14T17:31:00","date_gmt":"2025-02-14T12:01:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31063"},"modified":"2025-05-05T12:57:13","modified_gmt":"2025-05-05T07:27:13","slug":"metabolic-associated-steatohepatitis-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape","title":{"rendered":"Beyond Supportive Care: How New Drugs are Shaping Metabolic-associated Steatohepatitis (MASH) Treatment Outcomes"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d18cafdc9c7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d18cafdc9c7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape\/#The_tipping_point_How_REZDIFFRAs_approval_is_redefining_MASH_treatment\" >The tipping point: How REZDIFFRA\u2019s approval is redefining MASH treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape\/#The_rise_of_innovative_therapies_Transforming_MASH_treatment\" >The rise of innovative therapies: Transforming MASH treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape\/#Tailored_combinations_The_new_era_in_MASH_care\" >Tailored combinations: The new era in MASH care<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape\/#Which_emerging_drugs_will_dominate_the_future_of_MASH_treatment\" >Which emerging drugs will dominate the future of MASH treatment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape\/#MASH_market_forecast_A_billion-dollar_opportunity_in_the_making\" >MASH market forecast: A billion-dollar opportunity in the making<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape\/#Is_the_future_of_MASH_treatment_on_the_brink_of_transformation\" >Is the future of MASH treatment on the brink of transformation?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Metabolic-associated Steatohepatitis (MASH), previously known as Non-alcoholic Steatohepatitis (NASH), is a progressive liver condition characterized by fat buildup, inflammation, and liver cell damage. With rising rates of obesity, diabetes, and metabolic syndrome worldwide, MASH is becoming a major public health concern, often leading to fibrosis, cirrhosis, and even liver cancer. Unlike other liver diseases, MASH results from metabolic dysfunction rather than alcohol intake, making it a distinct target for therapeutic innovation.&nbsp;<\/p>\n\n\n\n<p><em>Nonalcoholic Steatohepatitis (NASH) was officially renamed to Metabolic Dysfunction-Associated Steatohepatitis (MASH) in 2023 by leading liver disease authorities, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), to reflect its metabolic origins better. For the latest insights, check out our updated <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/metabolic-dysfunction-associated-steatohepatitis-mash-market\"><strong><em>MASH Market Report<\/em><\/strong><\/a><\/p>\n\n\n\n<p>According to DelveInsight\u2019s estimates, in 2023, the prevalence of MASH was significant, with an estimated <strong>15.6 million diagnosed prevalent cases<\/strong> across the seven major markets (7MM), which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-tipping-point-how-rezdiffra-s-approval-is-redefining-mash-treatment\"><span class=\"ez-toc-section\" id=\"The_tipping_point_How_REZDIFFRAs_approval_is_redefining_MASH_treatment\"><\/span><strong>The tipping point: How REZDIFFRA\u2019s approval is redefining MASH treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The MASH treatment landscape has long been challenging due to its complex pathology. Driven by metabolic imbalances, MASH causes liver inflammation, fat buildup, and cellular damage, progressing to fibrosis, cirrhosis, or liver cancer. Despite the rising prevalence, effective therapies have been elusive\u2014until recent breakthroughs emerged.<\/p>\n\n\n\n<p>In 2024, a beacon of hope emerged with the <strong>FDA\u2019s approval of REZDIFFRA (Resmetirom)<\/strong>, a Thyroid Hormone Receptor Beta (THR\u03b2) agonist, marking a groundbreaking advancement as the first approved drug specifically for MASH treatment. Resmetirom offers an innovative therapeutic approach by addressing liver pathophysiology through the activation of thyroid hormone receptor-beta (THR\u03b2). Its targeted approach has opened new possibilities, moving beyond symptom management to potentially resolving core metabolic dysfunctions. This approval sets a new standard for future MASH treatments, highlighting the potential of THR\u03b2 agonists to meet rigorous regulatory requirements and deliver meaningful results for patients long left without effective options.<\/p>\n\n\n\n<p><strong><em>Want the full scoop on REZDIFFRA\u2019s rise? Check out our blog at <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/rezdiffra-journey-in-nash-treatment\"><strong><em>REZDIFFRA\u2019s Trailblazing Journey in MASH Treatment<\/em><\/strong><\/a><\/p>\n\n\n\n<p>In January 2025, Madrigal Pharmaceuticals participated in the <strong>J.P. Morgan Healthcare Conference<\/strong>, showcasing the performance of its drug thus far and outlining the company\u2019s goals for 2025. The company reported fourth-quarter REZDIFFRA revenues exceeding <strong>USD 100 million<\/strong>, contributing to total earnings of approximately <strong>USD 180 million<\/strong> from the drug in 2024. By the end of 2024, more than <strong>11,800 <\/strong>patients were using REZDIFFRA. Looking ahead, Madrigal plans to expand into the European market in the second half of 2025 and is awaiting results from its <strong>MAESTRO-NASH OUTCOMES trial<\/strong>, which focuses on REZDIFFRA in compensated cirrhosis. Madrigal&#8217;s continued success with REZDIFFRA positions the company for significant growth, with European expansion and trial results offering exciting prospects for 2025 and beyond.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-rise-of-innovative-therapies-transforming-mash-treatment\"><span class=\"ez-toc-section\" id=\"The_rise_of_innovative_therapies_Transforming_MASH_treatment\"><\/span><strong>The rise of innovative therapies: Transforming MASH treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/blog\/from-nash-to-mash\">treatment landscape for MASH<\/a> is witnessing significant growth in emerging therapies. With advancements in targeting precise molecular pathways and enhancing patient outcomes, the treatment paradigm is anticipated to shift considerably in the coming years.<\/p>\n\n\n\n<p>The leading drug class under investigation is <strong>THR-\u03b2 agonists<\/strong>, designed to enhance lipid metabolism and reduce liver fat. <strong>FGF and PPAR modulators<\/strong> address fibrosis and lipid dysregulation, respectively, while <strong>GLP-1 receptor agonists<\/strong>, primarily used in diabetes, show promise in reducing liver fat and inflammation. On the other hand, <strong>FXR agonists <\/strong>work by activating the Farnesoid X Receptor (FXR) to improve bile acid regulation and reduce inflammation. Additionally, newer classes like <strong>FASN inhibitors<\/strong>, <strong>CCR5 antagonists, <\/strong>and<strong> FFAR4 agonists<\/strong> target unique pathways related to lipid synthesis, immune response, and fatty acid regulation. Together, these agents represent a promising arsenal to combat MASH\u2019s complex pathology and improve patient outcomes.<\/p>\n\n\n\n<p>Alongside targeted drug classes for MASH, a range of emerging therapies with distinct mechanisms of action outside the primary drug categories is also being investigated. These include PXL065, a non-genomic TZD; LPCN 1144, an androgen receptor modulator; and Rencofilstat, a cyclophilin inhibitor. Belapectin (a Gal-3 inhibitor) and Miricorilant (a glucocorticoid receptor antagonist) address inflammation and fibrosis, while agents like ION224 and Ervogastat inhibit DGAT2. Cilofexor and firsocostat combine GLP-1 agonism with FASN inhibition, offering a multifaceted approach. Together, these drugs expand the treatment landscape, targeting MASH\u2019s complex pathology from multiple therapeutic angles.&nbsp;<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-63a3fdb2-7fff-4833-9cf9-efca6c509260\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"center\">\n<table style=\"border: none; border-collapse: collapse;\"><colgroup><col width=\"135\" \/><col width=\"168\" \/><col width=\"120\" \/><col width=\"51\" \/><col width=\"42\" \/><col width=\"132\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 13pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"6\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 8pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Leading Emerging Players in the MASH Treatment Landscape, Categorized by Drug Classes<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 13pt;\">\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Promising emerging therapies<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Company<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Target population by fibrosis stage<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Phase<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">RoA<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Molecule type<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"6\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">FXR agonists<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">HPG1860<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Hepagene (Shanghai) Co., Ltd.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F1, F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Small Molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"6\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">THR- &beta; agonists<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">VK2809<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Viking Therapeutics, Inc.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F1, F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Small Molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"6\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">FGF modulators<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">BIO89-100 (Pegozafermin)<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"> <\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span style=\"font-size: 0.6em; vertical-align: super;\">\u2206,\u2302<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">89bio, Inc.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F2, F3 and F4<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">SC<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PEGylated protein<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 24.177734375pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Efruxifermin <\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span style=\"font-size: 0.6em; vertical-align: super;\">\u2206,&loz;,\u2302<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Akero Therapeutics, Inc.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F1, F2, F3 and F4<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">SC<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Fusion protein<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">BOS-580<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Boston Pharmaceuticals<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">SC<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Recombinant protein<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"6\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PPAR modulators<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Lanifibranor (IVA337) <\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span style=\"font-size: 0.6em; vertical-align: super;\">\u2206,&loz;<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Inventiva Pharma<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Small molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">MSDC-0602K<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Cirius Therapeutics, Inc.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F1, F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Small molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Saroglitazar Magnesium<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Zydus Therapeutics<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Small molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"6\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">GLP-1 receptor agonists<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Semaglutide<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span style=\"font-size: 0.6em; vertical-align: super;\">\u2206<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Novo Nordisk A\/S<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">SC<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Polypeptide<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Survodutide (BI 456906)<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span style=\"font-size: 0.6em; vertical-align: super;\"> &loz;,\u2302<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Boehringer Ingelheim\/Zealand Pharma<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F1, F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">SC<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Peptides<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Efinopegdutide (MK-6024)<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span style=\"font-size: 0.6em; vertical-align: super;\"> &loz;<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Merck &amp; Co.\/Hanmi Pharmaceutical<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F2, F3 and F4<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">SC<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Peptides<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Tirzepatide<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Eli Lilly and Company<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">SC<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Peptides<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"6\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">FASN inhibitors<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 21.927734375pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Denifanstat<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span style=\"font-size: 0.6em; vertical-align: super;\">&loz;<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Sagimet Biosciences Inc.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Small molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"6\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">CCR5 antagonists<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Leronlimab (PRO 140)<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span style=\"font-size: 0.6em; vertical-align: super;\"> &loz;<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">CytoDyn, Inc.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F1, F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">SC<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Monoclonal antibody<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"6\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">FFAR4 agonists<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Icosabutate<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">NorthSea Therapeutics<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">F1, F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Synthetically modified Eicosapentanoic Acid (EPA) molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 15pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"6\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Designations:<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span style=\"font-size: 0.6em; vertical-align: super;\">\u2206<\/span><\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">: <\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Breakthrough Designation (BTD);<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span style=\"font-size: 0.6em; vertical-align: super;\">&loz;<\/span><\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">: <\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Fast Track Designation (FTD);<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span style=\"font-size: 0.6em; vertical-align: super;\">\u2302<\/span><\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">: <\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">PRIME<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>These treatments aim to address not only MASH but also specific stages of fibrosis, targeting distinct patient populations. A notable aspect is the range of innovative mechanisms of action (MoAs) adopted in various drug classes, highlighting the multifaceted nature of liver disease progression and treatment.<\/p>\n\n\n\n<p>The <strong>THR-\u03b2 agonist<\/strong> <strong>VK2809<\/strong> from <strong>Viking Therapeutics<\/strong> is emerging as a game-changer in MASH treatment, supported by groundbreaking clinical results. As part of the highest revenue-generating drug class in MASH, according to DelveInsight, VK2809 demonstrates exceptional potential. At the 75th Liver Meeting 2024, Viking shared final Phase IIb VOYAGE trial data. Patients on VK2809 showed significant liver fat reductions by Week 12, sustained through Week 52, with mean reductions of 37% to 55%. The response rate (\u226530% fat reduction) ranged from 64% to 88%, outperforming placebo. VK2809 also achieved NASH resolution in 63% to 75% of patients without worsening fibrosis, compared to 29% for placebo (<em>p<\/em> &lt; 0.05). Across all treatment groups, 69% reached NASH resolution (<em>p<\/em> &lt; 0.0001 vs. placebo). With a US launch<strong> <\/strong>anticipated for<strong> 2027<\/strong>, VK2809 underscores the transformative role of THR-\u03b2 agonists in <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-alcoholic-steatohepatitis-nash-pipeline-insight\">MASH therapy<\/a>.<\/p>\n\n\n\n<p>FGF modulators, another potent therapeutic class, hold significant promise, especially given their ability to stimulate Fibroblast Growth Factor 21 (FGF21), a key player in metabolic regulation. <strong>BIO89-100<\/strong>, also known as <strong>Pegozafermin<\/strong>, developed by <strong>89bio,<\/strong> is one of the front-runners within this class. Notably, Pegozafermin has shown potential for addressing both pre-cirrhotic and cirrhotic conditions in MASH patients and is expected to reach the market by <strong>2026 <\/strong>for pre-cirrhotic cases and by<strong> 2027<\/strong> for cirrhotic ones<strong>.<\/strong> Another FGF modulator, <strong>Efruxifermin by Akero Therapeutics<\/strong>, also targets multiple stages of fibrosis.<\/p>\n\n\n\n<p>Likewise, the FXR agonists, such as <strong>HPG1860 developed by Hepagene (Shanghai)<\/strong>, focus on activating the FXR to exert anti-inflammatory and anti-fibrotic effects. This class is currently advancing through clinical trials, with an anticipated market <strong>entry date of 2027<\/strong> in the United States.<\/p>\n\n\n\n<p>While these therapies showcase potential, the complexity of liver diseases like MASH demands a multifaceted approach. Consequently, emerging therapies are not limited to a single MoA or patient segment but span a variety of targets and administration routes. PPAR modulators, for instance, such as<strong> Lanifibranor<\/strong>, cater to patients with both MASH and type 2 diabetes mellitus. Lanifibranor, an oral PPAR agonist, is in Phase III trials. This drug leverages the peroxisome Proliferator-activated Receptor (PPAR) pathway to regulate lipid metabolism, a core aspect of MASH pathology, which is particularly relevant for patients with concurrent metabolic disorders.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/glucagon-like-peptide1-glp1-agonists-market-forecast\"><strong>GLP-1 receptor agonists<\/strong><\/a>, like <strong>Novo Nordisk&#8217;s Semaglutide<\/strong>, and dual-acting agents such as <strong>Boehringer Ingelheim&#8217;s Survodutide<\/strong>, are gaining recognition as pivotal drug classes in MASH treatment. These therapies not only address liver-specific metabolic dysfunctions but also offer systemic benefits, tackling broader metabolic issues.&nbsp;&nbsp;<\/p>\n\n\n\n<p><strong>Semaglutide<\/strong> is driving attention in the MASH treatment landscape with its dual administration options\u2014oral and subcutaneous\u2014enhancing its appeal for managing Type 2 diabetes and aiding weight loss. It has demonstrated potential in reducing biomarkers like ALT and hsCRP, signaling its efficacy in addressing metabolic dysfunctions linked to MASH. The <strong>FDA&#8217;s Breakthrough Therapy Designation,<\/strong> supported by positive Phase II trial outcomes in non-cirrhotic patients (F1\u2013F3), underscores its promise. However, its effectiveness in MASH-related cirrhosis (F4) remains unclear. With 34 active patents ensuring protection until at least 2032 and an anticipated <strong>US approval by 2028,<\/strong> semaglutide is well-positioned to achieve significant market penetration. This drug exemplifies the industry\u2019s shift towards therapies with dual or multi-mechanism approaches, providing comprehensive solutions for complex diseases like MASH.<\/p>\n\n\n\n<p>On the horizon are therapies with innovative targets, such as <strong>FASN inhibitors like Sagimet Biosciences\u2019 Denifanstat <\/strong>and <strong>CCR5 antagonists like Leronlimab from CytoDyn<\/strong>. These drugs focus on unique pathways involved in liver inflammation and fibrosis, reflecting the expanding scope of research in liver disease treatment. <strong>FFAR4 agonists<\/strong>, another emerging class, are also gaining attention, with <strong>NorthSea Therapeutics\u2019 Icosabutate<\/strong> targeting fatty acid receptors to reduce liver inflammation and fibrosis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-tailored-combinations-the-new-era-in-mash-care\"><span class=\"ez-toc-section\" id=\"Tailored_combinations_The_new_era_in_MASH_care\"><\/span><strong>Tailored combinations: The new era in MASH care<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The trend in emerging therapies aligns with a paradigm shift toward personalized medicine, where specific fibrosis stages and disease phenotypes are targeted with tailored therapeutic approaches. In the coming years, we can expect continued refinement in patient stratification, enabling healthcare providers to better match patients with therapies based on fibrosis stage and molecular profile. For example, while FXR agonists and THR-\u03b2 agonists may be more effective in patients with less severe fibrosis, advanced FGF modulators and combination therapies may play a critical role in managing later stages, including cirrhosis.<\/p>\n\n\n\n<p>Looking ahead, some key players in the <a href=\"https:\/\/www.delveinsight.com\/blog\/nash-commercial-activities\">MASH therapeutic market<\/a> are exploring combination therapies that could offer synergistic effects by targeting multiple pathways concurrently. For instance, <strong>Gilead Sciences and Novo Nordisk<\/strong> are investigating a combination of cilofexor, firsocostat, and semaglutide, targeting FXR, GLP-1, and JAK1 pathways. This combination therapy approach is particularly promising for treating patients with advanced fibrosis, where monotherapies have shown limited efficacy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_emerging_drugs_will_dominate_the_future_of_MASH_treatment\"><\/span><strong>Which emerging drugs will dominate the future of MASH treatment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Among the highly anticipated therapies set to launch by 2027, <strong>Inventiva Pharma\u2019s Lanifibranor <\/strong>is expected to take the largest share of the market, with analysts forecasting it as the top choice due to its comprehensive approach to addressing MASH. <strong>Akero Therapeutics\u2019 Efruxifermin is likely to follow closely as the second-largest contributor<\/strong>, offering versatility across different stages of MASH, which may boost its adoption. <strong>Viking Therapeutics\u2019 VK2809 <\/strong>rounds out the top three emerging treatments, with its targeted approach anticipated to make it a valuable option for early-stage patients. Together, these therapies are set to reshape the MASH landscape, expanding treatment options and addressing the complex needs of patients across various stages of disease progression.<\/p>\n\n\n\n<table style=\"border: none;\"><colgroup><col width=\"90\" \/><col width=\"76\" \/><col width=\"118\" \/><col width=\"73\" \/><col width=\"70\" \/><col width=\"81\" \/><col width=\"118\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 14.975999999999999pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"7\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 8pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Prominent Emerging Players in the Mash Treatment Landscape with Unique MoA Outside the Major Drug Classes<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Promising emerging therapies<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Company<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Target population by fibrosis stage<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Phase<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">RoA<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">MoA<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Molecule type<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">PXL065<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Poxel SA<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">F1, F2 or F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Non-genomic TZD actions<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Small molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">LPCN 1144<\/span><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\"><span style=\"font-size: 0.6em; vertical-align: super;\">&loz;<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Lipocine Inc.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">F1, F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Androgen receptor agonists<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Small molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">HTD1801<\/span><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\"><span style=\"font-size: 0.6em; vertical-align: super;\">&loz;<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">HighTide Biopharma<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Ionic salt of two active moieties (AMPK activator + gallstone dissolution agents)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Small molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Rencofilstat<\/span><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\"><span style=\"font-size: 0.6em; vertical-align: super;\">&loz;<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Hepion Pharmaceuticals, Inc.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Cyclophilin function inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Small molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Belapectin (Cirrhosis)<\/span><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\"><span style=\"font-size: 0.6em; vertical-align: super;\">&loz;<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Galectin Therapeutics Inc.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">F4<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">II\/III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">IV<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">GAL-3 inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Small molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Miricorilant (CORT118335)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Corcept Therapeutics<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">F1, F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Glucocorticoid receptor antagonists<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Small molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">ION224<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Ionis Pharmaceuticals<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">SC<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Diacylglycerol O-Acyltransferase (DGAT 2) antisense inhibitors&nbsp;<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">LIgand-Conjugated Antisense (LICA) medicine<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Ervogastat (PF-06865571) + Clesacostat (PF-05221304)<\/span><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\"><span style=\"font-size: 0.6em; vertical-align: super;\">&loz;<\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Pfizer<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">F2 and F3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">DGAT2i; Acetyl CoA carboxylase (ACC) Inhibitor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Small molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Cilofexor \/ firsocostat \/ semaglutide combination<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Gilead Sciences<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">F4<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">SC and oral<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">GLP-1 agonist + JAK1 inhibitor + FXR agonist<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Polypeptides: small molecule<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 4.968pt 4.968pt 4.968pt 4.968pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"7\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; color: #ff0000; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\"><span style=\"font-size: 0.6em; vertical-align: super;\">&loz;<\/span><\/span><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">: <\/span><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; vertical-align: baseline; white-space-collapse: preserve;\">Fast Track Designation (FTD)<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong><em>Find out which <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/promising-late-stage-nash-drugs\"><strong><em>late-stage MASH drug<\/em><\/strong><\/a><strong><em> will challenge REZDIFFRA\u2019s supremacy<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MASH_market_forecast_A_billion-dollar_opportunity_in_the_making\"><\/span><strong>MASH market forecast: A billion-dollar opportunity in the making<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/metabolic-dysfunction-associated-steatohepatitis-mash-market\"><strong>Metabolic Dysfunction-Associated Steatohepatitis Market Forecast Report<\/strong><\/a><strong>\u201d<\/strong>, the therapeutic market in 2023 was estimated to be <strong>USD 2 billion<\/strong>. Still, this figure is projected to swell significantly as emerging classes of drugs gain approval and are adopted in clinical practice. By 2034, revenue for MASH treatments in the 7MM (the United States, Germany, France, Italy, and Spain, the United Kingdom, and Japan) is expected to increase, driven largely by the adoption of novel drug classes like THR-\u03b2 agonists, FGF modulators, and PPAR modulators. Among these, <strong>THR-\u03b2 agonists<\/strong> are expected to capture the largest share, while FGF modulators and PPAR modulators are also projected to generate significant revenue, respectively.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_the_future_of_MASH_treatment_on_the_brink_of_transformation\"><\/span><strong>Is the future of MASH treatment on the brink of transformation?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Ultimately, the future of liver disease treatment is set to be one of incremental innovation and strategic advancements in drug design. Companies are not only focusing on bringing these therapies to market but also on demonstrating long-term efficacy and safety. As more data emerges from ongoing Phase II and III clinical trials, it is expected that healthcare providers and patients alike will benefit from a broader range of therapeutic options.&nbsp;<\/p>\n\n\n\n<p>This <a href=\"https:\/\/www.delveinsight.com\/blog\/novel-drug-classes-for-nash-treatment\">landscape of emerging MASH therapies<\/a> illustrates the pharmaceutical industry\u2019s commitment to addressing the global burden of liver diseases. Through continued innovation, it is anticipated that novel therapies will gradually replace supportive care as the standard of care, setting new benchmarks for efficacy, safety, and patient-centered outcomes. The journey to market for these drugs underscores the importance of robust clinical evidence and regulatory alignment, as well as the potential for significant financial returns for companies willing to invest in this challenging yet promising therapeutic area.<\/p>\n\n\n\n<p>As the market for MASH therapies evolves, ongoing monitoring of clinical and regulatory developments will be essential for stakeholders, including investors, healthcare providers, and patients. With promising pipelines and favorable market projections, the future of liver disease treatment is poised for a transformative shift, moving from palliative care to targeted therapies that address the root causes of disease progression. This shift is not only a testament to scientific progress but also a beacon of hope for millions of patients worldwide.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/metabolic-dysfunction-associated-steatohepatitis-mash-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18173719\/Metabolic-Dysfunction-Associated-Steatohepatitis-Market-Outook-1024x194.png\" alt=\"Metabolic Dysfunction-Associated Steatohepatitis Market Outook\" class=\"wp-image-30116\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18173719\/Metabolic-Dysfunction-Associated-Steatohepatitis-Market-Outook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18173719\/Metabolic-Dysfunction-Associated-Steatohepatitis-Market-Outook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18173719\/Metabolic-Dysfunction-Associated-Steatohepatitis-Market-Outook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18173719\/Metabolic-Dysfunction-Associated-Steatohepatitis-Market-Outook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18173719\/Metabolic-Dysfunction-Associated-Steatohepatitis-Market-Outook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/18173719\/Metabolic-Dysfunction-Associated-Steatohepatitis-Market-Outook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Metabolic-associated Steatohepatitis (MASH), previously known as Non-alcoholic Steatohepatitis (NASH), is a progressive liver condition characterized by fat buildup, inflammation, and liver cell damage. With rising rates of obesity, diabetes, and metabolic syndrome worldwide, MASH is becoming a major public health concern, often leading to fibrosis, cirrhosis, and even liver cancer. Unlike other liver diseases, MASH [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":31065,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22409,22318,22320,22450,1469,1470,21914],"industry":[17225],"therapeutic_areas":[17240],"class_list":["post-31063","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-glp-1-receptor","tag-mash","tag-mash-treatment","tag-metabolic-associated-steatohepatitis","tag-nash","tag-nonalcoholic-steatohepatitis","tag-rezdiffra","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Metabolic-associated Steatohepatitis Treatment | Key Insight<\/title>\n<meta name=\"description\" content=\"Landscape of emerging MASH treatment therapies illustrates industry\u2019s commitment to addressing global burden of liver diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Metabolic-associated Steatohepatitis Treatment | Key Insight\" \/>\n<meta property=\"og:description\" content=\"Landscape of emerging MASH treatment therapies illustrates industry\u2019s commitment to addressing global burden of liver diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-14T12:01:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T07:27:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/14151629\/metabolic-associated-steatohepatitis-treatment-landscape.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Metabolic-associated Steatohepatitis Treatment | Key Insight","description":"Landscape of emerging MASH treatment therapies illustrates industry\u2019s commitment to addressing global burden of liver diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"Metabolic-associated Steatohepatitis Treatment | Key Insight","og_description":"Landscape of emerging MASH treatment therapies illustrates industry\u2019s commitment to addressing global burden of liver diseases.","og_url":"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-02-14T12:01:00+00:00","article_modified_time":"2025-05-05T07:27:13+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/14151629\/metabolic-associated-steatohepatitis-treatment-landscape.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape","name":"Metabolic-associated Steatohepatitis Treatment | Key Insight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/14151629\/metabolic-associated-steatohepatitis-treatment-landscape.png","datePublished":"2025-02-14T12:01:00+00:00","dateModified":"2025-05-05T07:27:13+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Landscape of emerging MASH treatment therapies illustrates industry\u2019s commitment to addressing global burden of liver diseases.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/14151629\/metabolic-associated-steatohepatitis-treatment-landscape.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/14151629\/metabolic-associated-steatohepatitis-treatment-landscape.png","width":466,"height":284,"caption":"metabolic-associated-steatohepatitis-treatment-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/14151629\/metabolic-associated-steatohepatitis-treatment-landscape-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GLP-1 receptor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">MASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">MASH Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Metabolic-associated Steatohepatitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">NASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Nonalcoholic Steatohepatitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Rezdiffra<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">GLP-1 receptor<\/span>","<span class=\"advgb-post-tax-term\">MASH<\/span>","<span class=\"advgb-post-tax-term\">MASH Treatment<\/span>","<span class=\"advgb-post-tax-term\">Metabolic-associated Steatohepatitis<\/span>","<span class=\"advgb-post-tax-term\">NASH<\/span>","<span class=\"advgb-post-tax-term\">Nonalcoholic Steatohepatitis<\/span>","<span class=\"advgb-post-tax-term\">Rezdiffra<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 11 months ago"},"absolute_dates":{"created":"Posted on Feb 14, 2025","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Feb 14, 2025 5:31 pm","modified":"Updated on May 5, 2025 12:57 pm"},"featured_img_caption":"metabolic-associated-steatohepatitis-treatment-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31063"}],"version-history":[{"count":7,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31063\/revisions"}],"predecessor-version":[{"id":31627,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31063\/revisions\/31627"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31065"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31063"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31063"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31063"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31063"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}